Media, Health Workers, and Policy Makers' Relationship and Their Impact on Antimalarial Policy Adoption: A Population Genetics Perspective

Drug resistance negatively impacts malaria treatments, making treatment policy revision unavoidable. So far, studies relating sociopolitical and technical issues on policy change with malaria parasite genetic change are lacking. We have quantified the effect of malaria treatment policy on drug pressure and the influence of the media, policy makers, and health worker relationship on parasite population genetic change in Kilombro/Ulanga district. Cross-sectional surveys of asymptomatic infections conducted before, during and after the switch from chloroquine to sulphadoxine/pyrimethamine were used for genetic analysis of SP resistance genes in 4,513 asymptomatic infections identified, and their frequency change was compared with retrospective study of the documented process of policy change. Highly significant changes of dhfr and dhps resistance alleles occurred within one year of switch to SP first line, followed by a decline of their rate of selection caused by reduction of SP usage, as a result of negative media reports on SP usage and lack of adequate preparations.

[1]  R. Atun,et al.  Universal access to malaria medicines: innovation in financing and delivery , 2010, The Lancet.

[2]  H. Mshinda,et al.  Drug coverage in treatment of malaria and the consequences for resistance evolution - evidence from the use of sulphadoxine/pyrimethamine , 2010, Malaria Journal.

[3]  C. Rogier,et al.  Rapid Dissemination of Plasmodium falciparum Drug Resistance Despite Strictly Controlled Antimalarial Use , 2007, PloS one.

[4]  D. Ménard,et al.  Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. , 2006, The American journal of tropical medicine and hygiene.

[5]  S. Nsimba.  How sulfadoxine-pyrimethamine (SP) was perceived in some rural communities after phasing out chloroquine (CQ) as a first-line drug for uncomplicated malaria in Tanzania: lessons to learn towards moving from monotherapy to fixed combination therapy , 2006, Journal of ethnobiology and ethnomedicine.

[6]  H. Mshinda,et al.  Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies , 2005, Malaria Journal.

[7]  M. González-Block,et al.  Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug , 2005, Malaria Journal.

[8]  M. Petzold,et al.  Adoption of the new antimalarial drug policy in Tanzania – a cross‐sectional study in the community , 2005, Tropical medicine & international health : TM & IH.

[9]  F. Kironde,et al.  Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda , 2005, Tropical medicine & international health : TM & IH.

[10]  S. P. Kachur,et al.  Adherence to antimalarial combination therapy with sulfadoxine-pyrimethamine and artesunate in rural Tanzania. , 2004, The American journal of tropical medicine and hygiene.

[11]  B. Sharp,et al.  Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.

[12]  A. Mills,et al.  Retail supply of malaria‐related drugs in rural Tanzania: risks and opportunities , 2004, Tropical medicine & international health : TM & IH.

[13]  S. Lamola,et al.  Relationship between age, molecular markers, and response to sulphadoxine–pyrimethamine treatment in Kampala, Uganda , 2004, Tropical medicine & international health : TM & IH.

[14]  Nicholas J White,et al.  Antimalarial drug resistance. , 2004, The Journal of clinical investigation.

[15]  P. Rosenthal,et al.  Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. , 2003, The American journal of tropical medicine and hygiene.

[16]  B. Sharp,et al.  Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.

[17]  C. Drakeley,et al.  Molecular Determination of Point Mutation Haplotypes in the Dihydrofolate Reductase and Dihydropteroate Synthase of Plasmodium falciparum in Three Districts of Northern Tanzania , 2003, Antimicrobial Agents and Chemotherapy.

[18]  A. Kaneko,et al.  High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. , 2003, Acta tropica.

[19]  John C. Wootton,et al.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.

[20]  I. Adagu,et al.  Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  E. Nduati,et al.  Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. , 2000, The Journal of infectious diseases.

[22]  S. Hay,et al.  Annual Plasmodium falciparum entomological inoculation rates (EIR) across Africa: literature survey, Internet access and review. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[23]  A. Nzila,et al.  Towards an Understanding of the Mechanism of Pyrimethamine-Sulfadoxine Resistance in Plasmodium falciparum: Genotyping of Dihydrofolate Reductase and Dihydropteroate Synthase of Kenyan Parasites , 2000, Antimicrobial Agents and Chemotherapy.

[24]  S. Abdulla,et al.  The costs, effects and cost-effectiveness of changing the first line drug for the treatment of malaria in Tanzania , 2000 .

[25]  D. Conway,et al.  High recombination rate in natural populations of Plasmodium falciparum. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Bloland,et al.  Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub‐Saharan Africa , 1998, Tropical medicine & international health : TM & IH.

[27]  I. Hastings,et al.  A model for the origins and spread of drug-resistant malaria , 1997, Parasitology.

[28]  R. Steketee,et al.  Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. , 1993, The Journal of infectious diseases.